273 related articles for article (PubMed ID: 30854191)
1. Recent advances in understanding immune phenotypes of thyroid carcinomas: prognostication and emerging therapies.
Liotti F; Prevete N; Vecchio G; Melillo RM
F1000Res; 2019; 8():. PubMed ID: 30854191
[TBL] [Abstract][Full Text] [Related]
2. Immune Landscape of Thyroid Cancers: New Insights.
Menicali E; Guzzetti M; Morelli S; Moretti S; Puxeddu E
Front Endocrinol (Lausanne); 2020; 11():637826. PubMed ID: 33986723
[TBL] [Abstract][Full Text] [Related]
3. THERAPY OF ENDOCRINE DISEASE Immunotherapy of advanced thyroid cancer: from bench to bedside.
Moretti S; Menicali E; Nucci N; Guzzetti M; Morelli S; Puxeddu E
Eur J Endocrinol; 2020 Aug; 183(2):R41-R55. PubMed ID: 32449696
[TBL] [Abstract][Full Text] [Related]
4. Immune and Inflammatory Cells in Thyroid Cancer Microenvironment.
Ferrari SM; Fallahi P; Galdiero MR; Ruffilli I; Elia G; Ragusa F; Paparo SR; Patrizio A; Mazzi V; Varricchi G; Marone G; Antonelli A
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31500315
[TBL] [Abstract][Full Text] [Related]
5. Immunosuppressive cells in tumor immune escape and metastasis.
Liu Y; Cao X
J Mol Med (Berl); 2016 May; 94(5):509-22. PubMed ID: 26689709
[TBL] [Abstract][Full Text] [Related]
6. Immunology and Immunotherapy of Head and Neck Cancer.
Ferris RL
J Clin Oncol; 2015 Oct; 33(29):3293-304. PubMed ID: 26351330
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy.
Maccalli C; Parmiani G; Ferrone S
Immunol Invest; 2017 Apr; 46(3):221-238. PubMed ID: 28287848
[TBL] [Abstract][Full Text] [Related]
8. Bidirectional Crosstalk Between Cancer Stem Cells and Immune Cell Subsets.
Müller L; Tunger A; Plesca I; Wehner R; Temme A; Westphal D; Meier F; Bachmann M; Schmitz M
Front Immunol; 2020; 11():140. PubMed ID: 32117287
[TBL] [Abstract][Full Text] [Related]
9. Immune Escape Mechanism is Impaired in the Microenvironment of Thyroid Lymph Node Metastasis.
Cunha LL; Nonogaki S; Soares FA; Vassallo J; Ward LS
Endocr Pathol; 2017 Dec; 28(4):369-372. PubMed ID: 28730569
[TBL] [Abstract][Full Text] [Related]
10. Epigenetics and immunotherapy: The current state of play.
Dunn J; Rao S
Mol Immunol; 2017 Jul; 87():227-239. PubMed ID: 28511092
[TBL] [Abstract][Full Text] [Related]
11. Immune Profiling of Thyroid Carcinomas Suggests the Existence of Two Major Phenotypes: An ATC-Like and a PDTC-Like.
Giannini R; Moretti S; Ugolini C; Macerola E; Menicali E; Nucci N; Morelli S; Colella R; Mandarano M; Sidoni A; Panfili M; Basolo F; Puxeddu E
J Clin Endocrinol Metab; 2019 Aug; 104(8):3557-3575. PubMed ID: 30882858
[TBL] [Abstract][Full Text] [Related]
12. Current and future immunotherapies for thyroid cancer.
Antonelli A; Ferrari SM; Fallahi P
Expert Rev Anticancer Ther; 2018 Feb; 18(2):149-159. PubMed ID: 29241377
[TBL] [Abstract][Full Text] [Related]
13. Immune responses in the thyroid cancer microenvironment: making immunotherapy a possible mission.
Mould RC; van Vloten JP; AuYeung AWK; Karimi K; Bridle BW
Endocr Relat Cancer; 2017 Dec; 24(12):T311-T329. PubMed ID: 28912377
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulatory roles of nitric oxide in cancer: tumor microenvironment says "NO" to antitumor immune response.
PeÑarando J; Aranda E; RodrÍguez-Ariza A
Transl Res; 2019 Aug; 210():99-108. PubMed ID: 30953610
[TBL] [Abstract][Full Text] [Related]
15. Immuno-oncology-101: overview of major concepts and translational perspectives.
Allard B; Aspeslagh S; Garaud S; Dupont FA; Solinas C; Kok M; Routy B; Sotiriou C; Stagg J; Buisseret L
Semin Cancer Biol; 2018 Oct; 52(Pt 2):1-11. PubMed ID: 29428479
[TBL] [Abstract][Full Text] [Related]
16. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
Sweis RF; Galsky MD
Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
[TBL] [Abstract][Full Text] [Related]
17. Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics.
Mooradian MJ; Sullivan RJ
Future Oncol; 2017 Aug; 13(18):1649-1663. PubMed ID: 28776423
[TBL] [Abstract][Full Text] [Related]
18. Head and Neck Carcinoma Immunotherapy: Facts and Hopes.
Whiteside TL
Clin Cancer Res; 2018 Jan; 24(1):6-13. PubMed ID: 28751445
[TBL] [Abstract][Full Text] [Related]
19. Cancer-induced heterogeneous immunosuppressive tumor microenvironments and their personalized modulation.
Yaguchi T; Kawakami Y
Int Immunol; 2016 Aug; 28(8):393-9. PubMed ID: 27401477
[TBL] [Abstract][Full Text] [Related]
20. Cancer immunotherapies: advances and bottlenecks.
Rui R; Zhou L; He S
Front Immunol; 2023; 14():1212476. PubMed ID: 37691932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
